Joint Stock Company Kaspi.kz NASDAQ: KSPI reported second-quarter revenue growth of 15% and adjusted EBITDA growth of 5%, as gains in e-commerce and fintech were partly offset by higher funding costs and investments in Türkiye.
The Joint Corp. (JYNT) Q2 2026 Earnings Call Transcript
Joint NASDAQ: JYNT reported second-quarter results that reflected progress in its shift toward a capital-light, pure-play franchisor model, while management said patient retention improved to its highest level in more than five years.
The Joint Corp. (JYNT) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of $0.11. This compares to a loss of $0.06 per share a year ago.
Verizon Communications gained a net 184,000 postpaid phone connections in the second quarter, beating Wall Street's expectations on a metric that gauges new lucrative customers.
O expands into data centers with a new joint venture, targeting hyperscale assets and up to $1.4B in investments across the U.S. and Europe.
The London-listed telecommunications operator said the 50:50 joint venture would serve more than 3,000 customers in around 180 countries.
Wärtsilä Oyj Abp (WRTBY) Discusses Order Intake Growth, Portfolio Divestments, and New Energy Storage Joint Venture Transcript
Wärtsilä Oyj Abp (WRTBY) Discusses Joint Venture With RCT Solutions and Discontinuation of Energy Storage Reporting Segment Transcript
The Joint Corp (JYNT) is transitioning to a pure asset-light franchisor model, aiming to boost margins and free cash flow. JYNT's refranchising strategy targets 13-15% net margins versus 5.7% LTM, with system-wide sales growth hinging on stabilization of core operations. Clinic count has declined as underperformers are closed, but early signs show improving member retention and patient metrics.
According to Kiplinger, the Congressional Joint Economic Committee found Medicare Advantage is overpaying insurers by $212 per enrollee.
The Joint NASDAQ: JYNT reported first-quarter 2026 results that management said reflect improving profitability as the company nears completion of its “Joint 2.0” transformation into a “pure-play franchisor.” President and CEO Sanjiv Razdan highlighted progress on refranchising, marketing initiatives aimed at improving patient trends, and early moves to position the business for what the company calls “Joint 3.0” beginning in 2027.